WO2023227926 - CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS
National phase entry:
Publication Number
WO/2023/227926
Publication Date
30.11.2023
International Application No.
PCT/IB2022/054946
International Filing Date
26.05.2022
Title **
[English]
CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS
[French]
PROTÉINES DE SOIE D'ARAIGNÉE MODIFIÉES CHIMIQUEMENT
Applicants **
LATVIAN INSTITUTE OF ORGANIC SYNTHESIS
Inventors
JAUDZEMS, Kristaps
ROMANUKS, Viktors
FRIDMANIS, Jekabs
BULA, Anna Lina
SMITS, Gints
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1894 | |
| EPO | Filing, Examination, Granting | 8126 | |
| Japan | Filing, Examination, Granting | 2093 | |
| South Korea | Filing, Examination, Granting | 1853 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
19,306
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to recombinant spidroin bioconjugates (chemically modified engineered spider silk proteins). More particularly, the invention relates to recombinant spidroin bioconjugates with poly-ethyleneglycol polymers and their use in regenerative medicine.[French]
La présente invention concerne des bioconjugués de spidroïne recombinants (protéines de soie d'araignée modifiées chimiquement). Plus particulièrement, l'invention concerne des bioconjugués de spidroïne recombinants avec des polymères de polyéthylèneglycol et leur utilisation en médecine régénérative.